Protina will acquire a 26.66% stake in ABx BioSciences to secure artificial intelligence (AI)-based drug design technology.

In a regulatory filing on the 14th, Protina announced its decision to acquire 5,700 shares of ABx BioSciences, an AI drug design company, for 3.42 billion KRW. The scheduled acquisition date is July 16, 2026. The acquisition amount represents 12.05% of Protina's equity capital (28.37 billion KRW) as of the end of 2025.

This investment will be carried out through a combination of acquiring existing issued shares and participating in a third-party allotment capital increase. Specifically, Protina will acquire 1,600 existing shares for 960 million KRW and 4,100 new shares through a third-party allotment capital increase for 2.46 billion KRW. The acquisition price for both existing and new shares is 600,000 KRW per share. Upon completion of the acquisition, Protina will hold a total of 6,700 shares in ABx BioSciences, representing a 26.66% stake.

Regarding the purpose of the investment, Protina stated that it aims to "strengthen new drug development capabilities and pursue new business through the acquisition of de novo antibody design AI technology."

The acquisition target, ABx BioSciences, is a newly established corporation founded in 2026, with its primary business being the development of AI for drug design. As a newly established entity, its financial information was omitted from the filing. Protina added that while this acquisition is subject to filing a report on the main terms of asset acquisition, it does not constitute a backdoor listing and is not subject to reporting to the Korea Fair Trade Commission.